Search Results - "Lai, Robert Y"

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody by Swanson, Chad J, Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y K, Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A, Berry, Scott, Gordon, Robert, Kramer, Lynn D, Cummings, Jeffrey L

“…Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils,…”
Get full text

The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans by Chizh, Boris A., O’Donnell, Mary B., Napolitano, Antonella, Wang, Jie, Brooke, Allison C., Aylott, Mike C., Bullman, Jonathan N., Gray, Emily J., Lai, Robert Y., Williams, Pauline M., Appleby, Jonathan M.

“…TRPV1 is a cation channel activated by a range of noxious stimuli and highly expressed in nociceptive fibres. TRPV1 receptors are involved in pain and…”
Get full text

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody by Swanson, Chad J, Zhang, Yong, Dhadda, Shobha, Wang, Jinping, Kaplow, June, Lai, Robert Y K, Lannfelt, Lars, Bradley, Heather, Rabe, Martin, Koyama, Akihiko, Reyderman, Larisa, Berry, Donald A, Berry, Scott, Gordon, Robert, Kramer, Lynn D, Cummings, Jeffrey L

Get full text

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease by Lai, Robert Y K, Harrington, Charles R, Wischik, Claude M

“…Alzheimer's disease is characterized by redistribution of the tau protein pool from soluble to aggregated states. Aggregation forms proteolytically stable core…”
Get full text

A Randomized, Placebo-controlled Trial of the Analgesic Efficacy and Safety of the p38 MAP Kinase Inhibitor, Losmapimod, in Patients With Neuropathic Pain From Lumbosacral Radiculopathy by Ostenfeld, Thor, Krishen, Alok, Lai, Robert Y, Bullman, Jonathan, Green, Joanne, Anand, Praveen, Scholz, Joachim, Kelly, Madeline

“…OBJECTIVES:Preclinical studies have demonstrated involvement of p38 mitogen-activated protein kinase signaling pathways in the development of persistent pain…”
Get full text

Erratum: Lai, R.Y.K.; Harrington, C.R.; Wischik, C.M. Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease. Biomolecules 2016, 6, 19 by Lai, Robert Y K, Harrington, Charles R, Wischik, Claude M

“…The authors wish to correct their affiliations in this paper [1] as follows:[...]…”
Get full text

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury by Anand, Praveen, Shenoy, Ravikiran, Palmer, Joanne E, Baines, Amanda J, Lai, Robert Y.K, Robertson, Jonathan, Bird, Nick, Ostenfeld, Thor, Chizh, Boris A

“…Abstract Current treatments of neuropathic pain arising from conditions such as nerve injury/compression are only partially effective, and limited in their use…”
Get full text

Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease by Mikhno, Arthur, Devanand, Davangere, Pelton, Gregory, Cuasay, Katrina, Gunn, Roger, Upton, Neil, Lai, Robert Y, Libri, Vincenzo, Mann, J. John, Parsey, Ramin V

“…The positron emission tomography (PET) radioligand N-methyl-11C-2-(4-methylaminophenyl)-6-hydroxybenzothiazole (also known as 11C-6-OH-BTA-1 or 11C-PIB) binds…”
Get full text

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding by Červenka, Simon, Pålhagen, Sven E., Comley, Robert A., Panagiotidis, Georgios, Cselényi, Zsolt, Matthews, Julian C., Lai, Robert Y., Halldin, Christer, Farde, Lars

“…Clinical observations support a central role of the dopamine system in restless legs syndrome (RLS) but previous imaging studies of striatal dopamine…”
Get full text

A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease by Tzimopoulou, Sofia, Cunningham, Vincent J, Nichols, Thomas E, Searle, Graham, Bird, Nick P, Mistry, Prafull, Dixon, Ian J, Hallett, William A, Whitcher, Brandon, Brown, Andrew P, Zvartau-Hind, Marina, Lotay, Narinder, Lai, Robert Y K, Castiglia, Mary, Jeter, Barbara, Matthews, Julian C, Chen, Kewei, Bandy, Dan, Reiman, Eric M, Gold, Michael, Rabiner, Eugenii A, Matthews, Paul M

“…Here we report the first multi-center clinical trial in Alzheimer's disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures…”
Get more information

A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel-Based Morphometry by Comley, Robert A., Cervenka, Simon, Palhagen, Sven E., Panagiotidis, Georgios, Matthews, Julian C., Lai, Robert Y., Halldin, Christer, Farde, Lars, Nichols, Thomas E., Whitcher, Brandon J.

“…ABSTRACT BACKGROUND Restless legs syndrome (RLS) is a common neurological disorder the pathophysiology of which is incompletely understood. Four studies have…”
Get full text

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease by Irizarry, Michael C, Webb, David J, Bains, Chanchal, Barrett, Steven J, Lai, Robert Y, Laroche, Janette P, Hosford, David, Maher-Edwards, Gareth, Weil, John G

“…One limitation of several recent 24 week Alzheimer's disease (AD) clinical trials was the lack of cognitive decline detected by the AD Assessment…”
Get more information

P2-444: A novel potent histamine H3 receptor antagonist produces discrete changes in brain activity during learning and episodic memory: Implications for cognitive enhancement by Lai, Robert Y, Gregory, Sarah, Hall, D, Kenny, G, Caceres, Alejandro, Libri, Vincenzo, Williams, Steve C.R, Zelaya, Fernando O, Mehta, Mitul A

Get full text

P4-373: Predictors of placebo group decline in the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) in 24-week clinical trials of Alzheimer's disease by Irizarry, Michael C, Webb, David J, Bains, Chanchal, Barrett, Steven J, Lai, Robert Y, Laroche, Janette P, Hosford, David, Maher-Edwards, Gareth, Weil, John G

Get full text

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A[beta] protofibril antibody by Reyderman, Larisa, Bradley, Heather, Wang, Jinping, Swanson, Chad J, Berry, Scott, Lai, Robert Y. K, Koyama, Akihiko, Berry, Donald A, Kaplow, June, Kramer, Lynn D, Gordon, Robert, Dhadda, Shobha, Cummings, Jeffrey L, Lannfelt, Lars, Zhang, Yong, Rabe, Martin

Get full text

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A[beta] protofibril antibody by Reyderman, Larisa, Bradley, Heather, Wang, Jinping, Swanson, Chad J, Berry, Scott, Lai, Robert Y. K, Koyama, Akihiko, Berry, Donald A, Kaplow, June, Kramer, Lynn D, Gordon, Robert, Dhadda, Shobha, Cummings, Jeffrey L, Lannfelt, Lars, Zhang, Yong, Rabe, Martin

“…Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (A[beta]), with activity across oligomers,…”
Get full text

Evaluation of ^sup 11^C-GSK189254 as a Novel Radioligand for the H^sub 3^ Receptor in Humans Using PET by Ashworth, Sharon, Rabiner, Eugenii A, Gunn, Roger N, Plisson, Christophe, Wilson, Alan A, Comley, Robert A, Lai, Robert Y K, Gee, Antony D, Laruelle, Marc, Cunningham, Vincent J

“…The histamine H^sub 3^ receptor is implicated in the pathophysiology of several central nervous system disorders…”
Get full text

E2027, A NOVEL PHOSPHODIESTERASE-9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM by Landry, Ishani, Lai, Robert YK, Boyd, Peter, Aluri, Jagadeesh, Chang, Min-Kun, Schuck, Edgar L., Luthman, Johan

Get full text

P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM by Landry, Ishani, Lai, Robert YK, Boyd, Peter, Aluri, Jagadeesh, Chang, Min-Kun, Schuck, Edgar L., Luthman, Johan

Get full text

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES by Schuck, Edgar L., Reyderman, Larisa, Hayato, Seiichi, Takenaka, Osamu, Swanson, Chad J., Lai, Robert YK, Hussein, Ziad, Ferry, Jim

Get full text